OverT Bio Announces the Formation of the Clinical Advisory Board to Support the Clinical Development of OVT-101 in Ovarian Cancer and Other Solid Tumors
NEW YORK--(BUSINESS WIRE)-- #Biotech--OverT Bio forms Clinical Advisory Board to advance OVT-101, a scalable CAR-T therapy targeting CLDN6 for ovarian and other solid tumors.
MC
media contact
via Businesswire
Updated 2h ago
Source Verification
Corroboration Score: 1This story was independently reported by 1 sources. Click any source to read the original article.
Comments
0 commentsBe respectful and constructive.
Loading comments...
Previous
Is peer pressure more online in 2026?
Next
Trump delivers shocking low blow to former official whose wife was killed in terrorist attack
Related Articles
HealthFlight Attendant Thrown, Still Strapped in Seat Survives LaGuardia Crash
Anna Commander,Gabe Whisnant-10h ago-1 sources
HealthCoalition of Provider and Patient Groups Urges Reforms on the Use of Prior Authorization for Therapy Services
Pr Newswire-12h ago-1 sources
HealthPersonal Injury Attorney Ross F. Lagarde of Slidell, LA Explains How Louisiana Truck Accidents Differ From Car Crashes for HelloNation
Pr Newswire-12h ago-1 sources